Skip to main content
Delfa

← All assets

Lanabecestat

5 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

5

Ongoing

0

Recruiting

0

Completed

2

Sites

495

Countries

23

Endpoints

95

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 95 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
2
Phase 2/3
1
Phase 3
2

Trials by status

Completed
2
Terminated
3

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
22
Amyloid biomarkers
14
Other (unclassified)
13
Function / daily living
12
Safety / tolerability / PK
12
Tau biomarkers
10
Neuroimaging
6
Behavior / neuropsychiatric
4
Fluid / digital biomarkers
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 38 of 95 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

ADAS-CogCognition

8

ADCS-Activities of Daily Living (ADCS-ADL)Function

6

ADAS-CogOther

6

Mini-Mental State Examination (MMSE)Cognition

6

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

4

Neuropsychiatric Inventory (NPI)Behavior

4

Amyloid PET CentiloidAmyloid

4

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

5 of 5

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
DAYBREAK-ALZA Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia

Lanabecestat

Alzheimer’s disease

mild AD dementiaPh 3Terminated262Sep 20182results
AMARANTHAn Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

Lanabecestat

Alzheimer’s disease

MCI due to ADPh 2/3Terminated254Oct 20184results
NCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Lanabecestat

Alzheimer’s disease

Age ≥55Ph 3Terminated133Oct 2018-results
AZD3293TQTAZD3293 Thorough QT Study in Healthy Male Volunteers

Lanabecestat

Alzheimer’s disease

Age 18-55Ph 1Completed1May 2014-
NCT01795339A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients

Lanabecestat

Alzheimer’s disease

Alzheimer's diseasePh 1Completed1Mar 20141

Showing 1-5 of 5 trials